Development of a new benzophenone-diketopiperazine-type potent antimicrotubule agent possessing a 2-pyridine structure.

A new benzophenone-diketopiperazine-type potent antimicrotubule agent was developed by modifying the structure of the clinical candidate plinabulin (1). Although the right-hand imidazole ring with a branched alkyl chain at the 5-position in 1 was critical for the potency of the antimicrotubule activity, we successfully substituted this moiety with a simpler 2-pyridyl structure by converting the left-hand ring from a phenyl to a benzophenone structure without decreasing the potency. The resultant compound 6b (KPU-300) exhibited a potent cytotoxicity, with an IC50 value of 7.0 nM against HT-29 cells, by strongly binding to tubulin (K d = 1.3 μM) and inducing microtubule depolymerization.

[1]  S. Neuteboom,et al.  Synthesis and structure-activity relationships of benzophenone-bearing diketopiperazine-type anti-microtubule agents. , 2012, Bioorganic & medicinal chemistry.

[2]  M. Akamatsu,et al.  Synthesis and Structure−Activity Relationship Study of Antimicrotubule Agents Phenylahistin Derivatives with a Didehydropiperazine-2,5-dione Structure , 2012 .

[3]  H. Wakelee,et al.  Vascular Disrupting Agents , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  C. Dumontet,et al.  Microtubule-binding agents: a dynamic field of cancer therapeutics , 2010, Nature Reviews Drug Discovery.

[5]  E. Voest,et al.  Vascular disrupting agents (VDAs) in anticancer therapy. , 2010, Current clinical pharmacology.

[6]  Chryso Kanthou,et al.  Disrupting tumour blood vessels , 2005, Nature Reviews Cancer.

[7]  T. Mekhail,et al.  Paclitaxel in cancer therapy , 2002, Expert opinion on pharmacotherapy.

[8]  Y. Kiso,et al.  Total synthesis of anti-microtubule diketopiperazine derivatives: phenylahistin and aurantiamine. , 2000, The Journal of organic chemistry.

[9]  K. Kanoh,et al.  Synthesis and biological activities of phenylahistin derivatives. , 1999, Bioorganic & medicinal chemistry.

[10]  Y. Hayashi,et al.  Antitumor activity of phenylahistin in vitro and in vivo. , 1999, Bioscience, biotechnology, and biochemistry.

[11]  K. Kanoh,et al.  (-)-Phenylahistin arrests cells in mitosis by inhibiting tubulin polymerization. , 1999, The Journal of antibiotics.

[12]  T. Harada,et al.  (−)-Phenylahistin: A new mammalian cell cycle inhibitor produced by aspergillus ustus , 1997 .

[13]  M. Boyd,et al.  Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a) , 1995, Journal of medicinal chemistry.

[14]  R. Donehower,et al.  The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. , 1991, Pharmacology & therapeutics.

[15]  E. Hamel,et al.  Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. , 1989, Biochemistry.

[16]  S. M. Kupchan,et al.  Antimitotic and antitubulin activity of the tumor inhibitor steganacin. , 1977, Cancer research.

[17]  B. Bhattacharyya,et al.  Podophyllotoxin as a probe for the colchicine binding site of tubulin. , 1977, The Journal of biological chemistry.

[18]  M. Kelly,et al.  The biological effects and the chemical composition of podophyllin: a review. , 1954, Journal of the National Cancer Institute.

[19]  R. Ludford.  Colchicine in the Experimental Chemotherapy of Cancer , 1945 .

[20]  Paraskevi Giannakakou,et al.  Targeting microtubules for cancer chemotherapy. , 2005, Current medicinal chemistry. Anti-cancer agents.

[21]  E. Nogales.  Structural insights into microtubule function. , 2000, Annual review of biochemistry.